Glaxosmithkline Pharmaceuticals LtdNSE: GLAXO
Open the Glaxosmithkline Pharmaceuticals Ltd page
Follow Glaxosmithkline Pharmaceuticals LtdFree account. Get a note when Glaxosmithkline Pharmaceuticals Ltd files.
Q1 FY27 results analysis · August 03, 2026

Glaxosmithkline Pharmaceuticals Ltd Q1 FY27 Results Analysis: Revenue Surges 16.55%, Subsidiary PAT Loss Weighs

+15.7%PAT year on year, Rs. 237.18 Cr
Cofacto ResearchPublished August 03, 20262 min readPositive read
Quick summary

Glaxosmithkline Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 938.44 Cr (+16.55% YoY) and PAT growth of +15.69% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 03, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 938.44 Cr (+16.55% YoY)
PAT (Q1)Rs. 237.18 Cr (+15.69% YoY)
EBITDA margin31.49% (+29 bps YoY)
EPS (Q1)Rs. 14.00 (+15.70% YoY)
Market capRs. 45,134.11 Cr
CMPRs. 2,662.30

Quarter Snapshot

GLAXO reported strong 16.55% YoY revenue growth, recovering from supply chain disruptions and outpacing the IPM. Cost management improved material costs despite API price hikes. Concerns include higher other expenses and a subsidiary PAT loss.

Key Investment Insights

Key Positives

  • Consolidated revenue grew 16.55% YoY to Rs.938.44 Cr, recovering from supply chain disruption.
  • EBITDA margin expanded 29 bps YoY to 31.49% despite API price increases.
  • Material cost as % of revenue improved to 34.23% from 35.78% YoY, demonstrating cost management.
  • Revenue growth outpaced IPM growth of 10-11%, indicating market share gains.
  • PAT grew 15.69% YoY (consolidated) and 23.76% (standalone).
  • Supply chain constraints fully resolved, enabling strong growth.

Risk Factors

  • Other expenses increased to 16.85% of revenue from 14.11% in Q1 FY26, pressuring margins.
  • Subsidiary Biddle Sawyer recorded a PAT loss of Rs.16.15 Cr in Q1 FY27, reversing from a profit of Rs.24.16 Cr in FY26, dragging consolidated PAT.
  • Revenue declined 5.71% QoQ, consistent with seasonality but still a sequential decline.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.